Uncategorized
Lower doses of atropine yield less rebound
Whereas level I evidence supports the use of topical atropine to prevent myopic progression of up to 1 D per year in pediatric patients, higher doses have been shown to increase rates of myopic rebound, according to an American Academy of Ophthalmology report.Researchers reviewed 17 level I, II and III studies of children with myopia who had been treated with atropine ophthalmic solution of varying concentrations – 1%, 0.5%, 0.1% and 0.01% – to prevent myopia progression.